ArticleIranian Red Crescent medical journal2014
A multicenter study on expressions of vascular endothelial growth factor, matrix metallopeptidase-9 and tissue inhibitor of metalloproteinase-2 in oral and maxillofacial squamous cell carcinoma.
Article in Iranian Red Crescent medical journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 10 citations in OpenAlex.
- Low-activityExperimental and therapeutic medicine · 2021Article
- Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVascular endothelial growth factor (VEGF), matrix metallopeptidase-9 (MMP-9) and tissue inhibitor of metalloproteinase-2 (TIMP-2) are potential markers of oral and maxillofacial squamous cell carcinoma (SCC).
objectivesTo explore the association between expression of VEGF, MMP-9 and TIMP-2 in oral and maxillofacial SCC and clinicopathological factors. PATIENTS AND
methodsImmunohistochemical Envision method was used to analyze the expression of VEGF, MMP-9 and TIMP-2 in 54 cases of oral and maxillofacial SCC and the association with clinicopathological factors such as clinical staging and lymphatic metastasis.
resultsBrownish-yellow staining is correlated with positive expression of VEGF, MMP-9 and TIMP-2. Positive expression of VEGF and MMP-9 was correlated with lymphatic metastasis, and their positive expression rates were significantly higher in patients with lymphatic metastasis than those without it (VEGF: χ(2) = 30.00; P = 0.001; MMP-9: χ(2) = 18.27, P = 0.001). The positive expression rate of MMP-9 decreased at earlier clinical stages (P < 0.05). Positive expression of TIMP-2 was correlated with lymphatic metastasis, clinical staging and T classification. The positive rate of TIMP-2 expression in patients with lymphatic metastasis was significantly lower than those without it (χ(2) = 26.74, P = 0.002), which significantly reduced with increasing clinical stage and T classification (P < 0.05).
conclusionsLymphatic metastasis in patients with oral and maxillofacial SCC is closely related to the positive expression of VEGF, MMP-9 and TIMP-2. MMP-9 and TIMP-2 can affect the progression of cancer, which is valuable for studies on oral and maxillofacial SCC genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.